Since inception, Tetraphase has been using its proprietary chemistry technology to build a pipeline of antibiotic candidates to address the serious and growing unmet medical need in the treatment of multidrug-resistant bacterial infections.

Tetraphase Pipeline


We are developing our lead product candidate, eravacycline, as a broad-spectrum intravenous and oral antibiotic for the treatment of multidrug-resistant (MDR) infections, including those caused by MDR Gram-negative bacteria. We developed eravacycline using our proprietary chemistry technology. 
Eravacycline is a novel, fully synthetic tetracycline antibiotic. We are currently investigating the safety and efficacy of eravacycline in a Phase 3 program called IGNITE (Investigating Gram-negative Infections Treated with Eravacycline) for the treatment of complicated intra-abdominal infections (cIAI)(IGNITE 1) and complicated urinary tract infections (cUTI)(IGNITE 2). With top-line data from both studies expected by mid-year 2015, we expect to be able to file for U.S. regulatory approval for eravacycline for both indications by the end of 2015.

TP-271, a novel antibiotic currently in preclinical development, is being developed to combat respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens. As development continues, TP-271 is anticipated to protect against certain biothreats agents, including Francisella tularensis, which causes tularemia; Yersinia pestis, which causes bubonic plague; Bacillus anthracis, which causes anthrax disease; and bacterial pathogens associated with community-acquired bacterial pneumonia (CABP), a significant public health threat and commercial market opportunity.

We are developing TP-271 with the financial assistance of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), which awarded us a $36 million contract in October 2011 to support TP-271's development, manufacturing, and clinical activities, from which we may receive up to approximately $13 million in funding.

2nd Generation Gram-negative Program
We are using our proprietary chemistry technology to pursue the discovery and development of additional tetracycline-derived compounds effective against the most urgent multidrug-resistant Gram-negative bacterial health threats identified by the CDC in a September 2013 report. Pathogens targeted include carbapenem-resistant variants of Klebsiella pneumoniae, Acinetobacter baumanni, Escherichia coli and Pseudomonas aeruginosa. We have generated compounds that have demonstrated potent activity against a broad range of these multidrug-resistant Gram-negative pathogens. We have identified a lead preclinical candidate from these compounds and expect to advance this compound into preclinical studies during the second half of 2014.



Print this Page  
Entire Movie Background Platform Chemical Diversity